The artificial pancreas — the automated closed-loop control of diabetes mellitus — made its first outpatient strides in 2011. In 2017, the results of long-term clinical trials on the artificial pancreas were published, the first hybrid commercial artificial pancreas system was approved and the artificial pancreas was tested under increasingly demanding conditions. Thus, artificial pancreas technology is here to stay.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Developing and adopting safe and effective digital biomarkers to improve patient outcomes
npj Digital Medicine Open Access 11 March 2019
-
Automated closed-loop control of diabetes: the artificial pancreas
Bioelectronic Medicine Open Access 07 November 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7, 385–395 (2011).
Cefalu, W. T. & Tamborlane, W. V. The artificial pancreas: are we there yet? Diabetes Care 37, 1182–1183 (2014).
Kovatchev, B. P., Tamborlane, W. V., Cefalu, W. T. & Cobelli, C. The artificial pancreas in 2016: a digital treatment ecosystem for diabetes. Diabetes Care 39, 1123–1127 (2016).
Bergenstal, R. M. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316, 1407–1408 (2016).
Garg, S. K. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol. Ther. 19, 155–163 (2017).
Bally, L. et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol. 5, 261–270 (2017).
Dassau, E. et al. 12-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia. Diabetes Care http://dx.doi.org/10.2337/dc17-1188 (2017).
Dovc, K. et al. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia 60, 2157–2167 (2017).
Breton, M. D. et al. Closed loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes Care http://dx.doi.org/10.2337/dc17-0883 (2017).
National Institutes of Health. Four pivotal NIH-funded artificial pancreas research efforts begin. NIH https://www.nih.gov/news-events/news-releases/four-pivotal-nih-funded-artificial-pancreas-research-efforts-begin (2017).
Acknowledgements
The author's work on closed-loop control is supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants DP3 DK101055, RO1 DK 085623 and UC4 108483 – the International Diabetes Closed-Loop Trial, and by the University of Virginia's Strategic Investment in Type 1 Diabetes.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.K. has received speaking engagements/honoraria from Dexcom and Sanofi; research support managed by the University of Virginia from Ascensia Diabetes Care, Dexcom, Roche Diagnostics and Tandem Diabetes Care; patent royalties managed by the University of Virginia from Johnson & Johnson and Sanofi; and is shareholder/board member of TypeZero Technologies, Inc.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kovatchev, B. The year of transition from research to clinical practice. Nat Rev Endocrinol 14, 74–76 (2018). https://doi.org/10.1038/nrendo.2017.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.170
This article is cited by
-
Insulin detection in diabetes mellitus: challenges and new prospects
Nature Reviews Endocrinology (2023)
-
Developing and adopting safe and effective digital biomarkers to improve patient outcomes
npj Digital Medicine (2019)
-
Automated closed-loop control of diabetes: the artificial pancreas
Bioelectronic Medicine (2018)